Companies/EU/ALCLS

CELLECTIS S.A.

Last · Paris€1.074-0.054 (-4.79%)stale · yahoo · 46h ago
Vol 70.6K ≈ 74.8K
Market cap€108.2M72.7M sh
P/E · TTM-2.0fwd -0.7 · eps -0.55 · loss
Beta2.91vs S&P 500
Div yield0.00%annual · TTM
52w range
€1.04€4.84
Volume366.4Ksession

Issuer

Legal nameCELLECTIS S.A.
HQEurope (EU)
ListingEU ALCLS
ISINFR0010425595
LEI5493000KKX5VQ37Q2W83
SectorHealthcare
IndustryBiotechnology & Medical Research
CurrencyEUR
Entity registryisin:FR0010425595
CIK0001627281
Websitewww.cellectis.com
LinkedIn
Employees227
AddressCellectis SA 8, rue de la Croix Jarry 75013, Paris +33 1 81 69 16 00
Headline financial metrics
Revenue€283
Period2024
Loading chart…

OpenFilings analyst

Our analyst

ANNUAL · 2025-03-13

From latest ANNUAL · 2025-03-13

  • Net Margin Sharply Negative

Red flags

  • Net Margin Sharply Negative — Net margin -14768.6%

Upcoming earnings

1 event
4:30 PM UTC+1
Period
Sep 2026
Est. EPS
—
Est. revenue
13.5M
View upcoming earnings →

Earnings transcripts

2 recent

Press & signals

3 of 9 recent
  • GlobeNewswire

    Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company

  • GlobeNewswire

    Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update

  • GlobeNewswire

    Monthly information on share capital and company voting rights

The rest of this company's wire — with summaries and source links — is part of Pro.

See plans

Documents

FormReporting forFiledFlags
otherLegal Notice- subscription and contact forms- CellectisIR
—2026-12-31≈0
DISCLOSUREMonthly information on share capital and company voting rights
2026-10-062026-10-060
4BDIF 2026DD1140692
2026-09-292026-09-290
4BDIF 2026DD1139480
2026-09-222026-09-220
Showing 5 of 623 filings